These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15645556)

  • 21. The Vioxx debacle revisited.
    Abeles M; Abeles AM
    Am J Med; 2005 Sep; 118(9):1057-8. PubMed ID: 16164907
    [No Abstract]   [Full Text] [Related]  

  • 22. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cyclooxygenase-2 inhibitors and the ethics of research].
    Gherardi CR
    Medicina (B Aires); 2005; 65(5):476. PubMed ID: 16296649
    [No Abstract]   [Full Text] [Related]  

  • 24. COX-2 inhibitors and heart.
    Manoria P; Manoria PC
    Indian Heart J; 2005; 57(6):772-7. PubMed ID: 16521658
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
    Bolten WW; Reiter S;
    Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
    [No Abstract]   [Full Text] [Related]  

  • 26. [Rapid and safe pain management. Promising new cyclooxygenase inhibitor].
    MMW Fortschr Med; 2002 Jul; 144(29-30):53. PubMed ID: 12219614
    [No Abstract]   [Full Text] [Related]  

  • 27. Rescuing COX-2 inhibitors from the waste bin.
    Albini A; Noonan DM
    J Natl Cancer Inst; 2005 Jun; 97(11):859-60. PubMed ID: 15928309
    [No Abstract]   [Full Text] [Related]  

  • 28. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
    Epstein RA
    Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cyclooxygenase inhibitors: a never ending story?].
    Macrì R; Manfredi C
    G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790
    [No Abstract]   [Full Text] [Related]  

  • 30. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
    Vanchieri C
    J Natl Cancer Inst; 2005 Apr; 97(8):552-3. PubMed ID: 15840872
    [No Abstract]   [Full Text] [Related]  

  • 31. Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now.
    Finckh A; Aronson MD
    Ann Intern Med; 2005 Feb; 142(3):212-4. PubMed ID: 15684210
    [No Abstract]   [Full Text] [Related]  

  • 32. Cox-2 inhibitors: still no decisive action.
    Prescrire Int; 2005 Jun; 14(77):102. PubMed ID: 15981408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unconvincing Pfizer and uncertain crucifixions.
    Abbasi K
    J R Soc Med; 2006 Apr; 99(4):163. PubMed ID: 16574956
    [No Abstract]   [Full Text] [Related]  

  • 34. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 36. Celecoxib and cardiovascular risks.
    Brophy JM
    Expert Opin Drug Saf; 2005 Nov; 4(6):1005-15. PubMed ID: 16255660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Yellow light on pain relievers. American Heart Association guidelines recommend using caution for all medications that ease pain.
    Harv Heart Lett; 2007 Jun; 17(10):1-3. PubMed ID: 17654797
    [No Abstract]   [Full Text] [Related]  

  • 38. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
    Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig.
    Timmers L; Sluijter JP; Verlaan CW; Steendijk P; Cramer MJ; Emons M; Strijder C; Gründeman PF; Sze SK; Hua L; Piek JJ; Borst C; Pasterkamp G; de Kleijn DP
    Circulation; 2007 Jan; 115(3):326-32. PubMed ID: 17210840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.